[
  {
    "ts": "2025-09-10T11:03:00+00:00",
    "headline": "Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More",
    "summary": "The global chronic myelomonocytic leukemia (CMML) market is set for significant growth due to rising CMML cases, advanced targeted therapies, and increased disease awareness. Recognized as a rare leukemia, CMML's prevalence, especially in aging populations, propels demand for effective treatments. Market growth is fueled by breakthroughs in targeted therapies, immunotherapies, and innovative solutions like CAR-T cell therapies. Enhanced healthcare infrastructure, patient awareness, and reimburse",
    "url": "https://finance.yahoo.com/news/chronic-myelomonocytic-leukemia-market-analysis-110300842.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "22a514e8-53fa-3706-b21c-403994828d40",
      "content": {
        "id": "22a514e8-53fa-3706-b21c-403994828d40",
        "contentType": "STORY",
        "title": "Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More",
        "description": "",
        "summary": "The global chronic myelomonocytic leukemia (CMML) market is set for significant growth due to rising CMML cases, advanced targeted therapies, and increased disease awareness. Recognized as a rare leukemia, CMML's prevalence, especially in aging populations, propels demand for effective treatments. Market growth is fueled by breakthroughs in targeted therapies, immunotherapies, and innovative solutions like CAR-T cell therapies. Enhanced healthcare infrastructure, patient awareness, and reimburse",
        "pubDate": "2025-09-10T11:03:00Z",
        "displayTime": "2025-09-10T11:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chronic-myelomonocytic-leukemia-market-analysis-110300842.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chronic-myelomonocytic-leukemia-market-analysis-110300842.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GSK.L"
            },
            {
              "symbol": "JAZZ"
            },
            {
              "symbol": "NOVN.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-10T10:34:00+00:00",
    "headline": "US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche",
    "summary": "The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 billion by 2033, with an 8.22% CAGR from 2025 to 2033. This growth is driven by advancements in gene therapy, increased access to CFTR modulators, and robust research initiatives. Key players like Vertex Pharmaceuticals and Abbvie leverage developments like Trikafta, expanding the therapeutic market. Challenges including high treatment costs and limited rural access persist",
    "url": "https://finance.yahoo.com/news/us-cystic-fibrosis-therapeutics-market-103400071.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "4e37f7e5-480a-3669-9b03-30caae5a9d20",
      "content": {
        "id": "4e37f7e5-480a-3669-9b03-30caae5a9d20",
        "contentType": "STORY",
        "title": "US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche",
        "description": "",
        "summary": "The United States Cystic Fibrosis Therapeutics Market is set to grow from an estimated US$ 2.32 billion in 2024 to US$ 4.72 billion by 2033, with an 8.22% CAGR from 2025 to 2033. This growth is driven by advancements in gene therapy, increased access to CFTR modulators, and robust research initiatives. Key players like Vertex Pharmaceuticals and Abbvie leverage developments like Trikafta, expanding the therapeutic market. Challenges including high treatment costs and limited rural access persist",
        "pubDate": "2025-09-10T10:34:00Z",
        "displayTime": "2025-09-10T10:34:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/bbd347c35cc79a889f6d26b4ba874682",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "U.S. Cystic Fibrosis Therapeutics Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B5_Ztd8MtV4mXCyDBhj8nA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/bbd347c35cc79a889f6d26b4ba874682.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SejLxmS9nmNDY2wUw5.hcA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/bbd347c35cc79a889f6d26b4ba874682.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/us-cystic-fibrosis-therapeutics-market-103400071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-cystic-fibrosis-therapeutics-market-103400071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]